IMMU-130, an SN-38 antibody-drug conjugate (ADC) targeting CEACAM5, is therapeutically active in metastatic colorectal cancer (mCRC): Initial clinical results of two phase I studies Meeting Abstract
| Authors: | Segal, N. H.; Dotan, E.; Berlin, J. D.; Starodub, A. N.; Guarino, M. J.; Saltz, L. B.; Maliakal, P. P.; Govindan, S. V.; Wegener, W. A.; Sharkey, R. M.; Goldenberg, D. M. |
| Abstract Title: | IMMU-130, an SN-38 antibody-drug conjugate (ADC) targeting CEACAM5, is therapeutically active in metastatic colorectal cancer (mCRC): Initial clinical results of two phase I studies |
| Meeting Title: | 105th Annual Meeting of the American Association for Cancer Research (AACR) |
| Journal Title: | Cancer Research |
| Volume: | 74 |
| Issue: | 19 Suppl. |
| Meeting Dates: | 2014 Apr 5-9 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2014-10-01 |
| Language: | English |
| ACCESSION: | WOS:000349910205040 |
| DOI: | 10.1158/1538-7445.am2014-ct211 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: CT211 -- 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR) -- APR 05-09, 2014 -- San Diego, CA -- S -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
